Fruquintinib combined with FOLFIRI/mFOLFOX6 as second-line treatment in patients with RAS-mutant metastatic colorectal cancer (mCRC): A multicenter, open-label, phase II study. This is an ASCO Meeting ...
Evaluating triple therapy with lenvatinib, PD-1 inhibitor and transarterial chemoembolization for unresectable intrahepatic cholangiocarcinoma: A retrospective study. The efficacy and safety of ...
Objectives Studies on ageing trajectories typically foreground intrinsic capacities and focus on frailty and mortality outcomes. Instead, research capturing aspects of people’s living environment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results